深圳大学西丽校区

学术讲座

【医学部】学术讲座--Targeting cancer stem cells to prevent disease relapse

2019年04月26日

题  目:Targeting cancer stem  cells to prevent disease relapse

主讲嘉宾:CHRISTOPHER HEESCHEN 教授

时  间:201958日上午10:00-11:00

地  点:深圳大学医学部A6-701

主 持 人:朱卫国 教授

报告内容简介:

The aim of Prof. Chris Heeschen’s research  programme is to improve the still dismal outcome of patients with pancreatic  cancer. He has shown, down to a single cell, that pancreatic cancer contains  highly tumourigenic and metastatic cancer stem cells (CSC). Their specific  genetic ablation prevented disease relapse, encouraging his group to  systematically develop treatment strategies that eliminate all cancer cells  including CSC. He has established  an array of novel technologies, enabling him to isolate, track and study rare  human CSC in real time. He uses advanced genetic and pharmacological tools to  identify novel CSC signalling elements as well as cancer-specific immune  targets. Preclinical validation studies include the use of novel switchable  mouse models and humanised xenograft models. These multidisciplinary efforts  allowed his group to establish several highly effective multimodal treatment  strategies as well as tuneable CAR T-cell immunotherapies. Prof. Heeschen now  aims to translate these findings into novel precision medicine clinical trials,  CSC-centred and liquid biopsy-guided, and thereby contribute to a better outcome  for pancreatic cancer patients.

 

报告嘉宾简介:

Prof. Chris Heeschen obtained his MD in  1997 at the Free University of Berlin (Germany). During his clinical training in  Internal Medicine (1996 – 2004), he also earned a PhD for his studies in basic  mechanisms of angiogenesis and vasculogenic stem cells at the Falk  Cardiovascular Research Centre at Stanford University (USA). Prof. Heeschen  subsequently became Head of the Department Experimental Medicine at  Ludwig-Maximilian-University in Munich (Germany) and shifted his research focus  from stem cells in regenerative medicine to cancer. Since then he held several  leadership positions including the Clinical Research Programme at the Spanish  National Cancer Research Centre (2008,) and the Centre for Stem Cells in Cancer  & Ageing at the Barts Cancer Institute in London (2013). In 2018, he joined  UNSW Sydney to establish his translational research program, with a particular  focus on pancreatic cancer. Prof. Heeschen has an excellent track record with  currently 28,540 citations (9,844 since 2014) and an h-index of 67. Eighteen of  his papers have been cited >500 times, seven papers >1,000  times.